DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2011; 136(36): 1790-1795DOI: 10.1055/s-0031-1286104 Übersicht | Review articleGastroenterologie© Georg Thieme Verlag KG Stuttgart · New YorkHelicobacter pylori: Infektion mit lokalen Komplikationen und systemischen AuswirkungenHelicobacter pylori: an infection with local complications and systemic effectsM. Selgrad1 , J. Bornschein1 , P. Malfertheiner1 1Klinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-von-Guericke-Universität Magdeburg Recommend Article Abstract Buy Article Schlüsselwörter Helicobacter pylori - Prävention des Magenkarzinoms - extragastrale Erkrankungen - idiopathische thrombozytopenische Pupura Keywords Helicobacter pylori - prevention of gastric cancer - extragastric diseases - idiopathic thrombozytopenic purpura Full Text References Literatur 1 Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001; 49 347-353 2 Abdullahi M, Annibale B, Capoccia D. et al . The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg. 2008; 18 1450-1454 3 Anderson H R. Prevalence of asthma. BMJ. 2005; 330 1037-1028 4 Arnold D M, Bernotas A, Nazi I. et al . Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection. Haematologica. 2009; 94 850-856 5 Arslan E, Atilgan H, Yavasoglu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Intern Med. 2009; 20 695-697 6 Asaka M, Kato M, Takahashi S. et al . Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010; 15 1-20 7 Bago J, Majstorovic K, Belosic-Halle Z. et al . Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days moxifloxacin based therapy for the eradication. Ann Clin Microbiol Antimicrob. 2010; 9 13 8 Blaser M J, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy?. Gut. 2008; 57 561-567 9 Bornschein J, Selgrad M, Warnecke M. et al . H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci. 2010; 55 3124-3131 10 Bourke B, Ceponis P, Chiba N. et al . Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents – an evidence-based evaluation. Can J Gastroenterol. 2005; 19 399-408 11 Caselli M, Zullo A, Maconi G. et al . „Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007; 39 782-789 12 Cassaro M, Rugge M, Gutierrez O. et al . Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol. 2000; 95 1431-1438 13 Chey W D, Wong B C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102 1808-2185 14 Codolo G, Mazzi P, Amedei A. et al . The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol. 2008; 10 2355-2363 15 D’Elios M M, Codolo G, Amedei A. et al . Helicobacter pylori, asthma and allergy. FEMS Immunol Med Microbiol. 2009; 56 1-8 16 de Vries A C, Kuipers E J. Helicobacter pylori infection and nonmalignant diseases. Helicobacter. 2010; 15 Suppl 1 29-33 17 de Vries A C, Kuipers E J, Rauws E A. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn?. Am J Gastroenterol. 2009; 104 1342-1345 18 de Vries A C, van Grieken N C, Looman C W. et al . Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008; 134 945-952 19 MF, Cavallaro L G, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig Dis. 2006; 24 113-130 20 Dore M P, Graham D Y, Mele R. et al . Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002; 97 857-860 21 Ekstrom A M, Held M, Hansson L E. et al . Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001; 121 784-791 22 Essa A S, Kramer J R, Graham D Y. et al . Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing „concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14 109-118 23 Ferrara M, Capozzi L, Russo R. Effect of Helicobacter pylori eradication on platelet count in children with chronic idiopathic thrombocytopenic purpura. Hematology. 2009; 14 282-285 24 Fischbach W, Malfertheiner P, Hoffmann J C. et al . S3-guideline „helicobacter pylori and gastroduodenal ulcer disease” of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol. 2009; 47 1230-1263 25 Fock K M, Katelaris P, Sugano K. et al . Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24 1587-600 26 Fuccio L, Minardi M E, Zagari R M. et al . Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007; 147 553-562 27 Fuccio L, Zagari R M, Eusebi L H. et al . Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med. 2009; 151 121-128 28 Fukase K, Kato M, Kikuchi S. et al . Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372 392-397 29 Gasbarrini A, Franceschi F, Tartaglione R. et al . Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998; 352 878 30 Gatta L, Vakil N, Leandro G. et al . Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009; 104 3069-3079 31 Gene E, Calvet X, Azagra R. et al . Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther. 2003; 18 543-544 32 Huang X, Qu X, Yan W. et al . Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J. 2010; 86 272-278 33 Kamada T, Hata J, Sugiu K. et al . Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005; 21 1121-1126 34 Karlsson E A, Beck M A. The burden of obesity on infectious disease. Exp Biol Med. 2010; 235 1412-1424 35 Kodama M, Kitadai Y, Ito M. et al . Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter. 2007; 12 36-42 36 Liou J M, Lin J T, Chang C Y. et al . Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut. 2010; 59 572-578 37 Mahachai V, Sirimontaporn N, Tumwasorn S. et al . Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol. 2011; 26 825-828 38 Malfertheiner P, Bazzoli F, Delchier J C. et al . Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy. Lancet. 2011; 377 905-913 39 Malfertheiner P, Megraud F, O’Morain C. et al . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56 772-781 40 Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol. 2010; 26 618-623 41 Malfertheiner P, Sipponen P, Naumann M. et al . Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005; 100 2100-2115 42 Megraud F. Helicobacter pylori and antibiotic resistance. Gut. 2007; 56 1502 43 Moayyedi P. Should triple therapy for Helicobacter pylori eradication be prescribed for 1 week or 2 weeks?. Nat Clin Pract Gastroenterol Hepatol. 2007; 4 596-597 44 Nista E C, Candelli M, Zocco M A. et al . Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005; 21 1241-1247 45 Ohkusa T, Fujiki K, Takashimizu I. et al . Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001; 134 380-386 46 Robinson K, Kenefeck R, Pidgeon E L. et al . Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut. 2008; 57 1375-1385 47 Romano M, Cuomo A, Gravina A G. et al . Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication. Gut. 2010; 59 1465-1470 48 Rugge M, Meggio A, Pennelli G. et al . Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007; 56 631-636 49 Sarker S A, Mahmud H, Davidsson L. et al . Causal relationship of Helicobacter pylori with iron-deficiency anemia or failure of iron supplementation in children. Gastroenterology. 2008; 135 1534-1542 50 Strachan D P. Hay fever, hygiene, and household size. BMJ. 1989; 299 1259-1260 51 Suzuki T, Matsuo K, Ito H. et al . Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006; 119 217-224 52 Take S, Mizuno M, Ishiki K. et al . Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007; 42 Suppl 17 21-27 53 Uemura N, Mukai T, Okamoto S. et al . Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997; 6 639-642 54 Uemura N, Okamoto S, Yamamoto S. et al . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345 784-789 55 Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. Curr Opin Clin Nutr Metab Care. 2009; 12 522-525 56 Wong B C, Lam S K, Wong W M. et al . Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. JAMA. 2004; 291 187-194 57 Wu D C, Hsu P I, Wu J Y. et al . Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010; 8 36-41 Prof. Dr. Dres. h. c. Peter Malfertheiner Klinik für Gastroenterologie, Hepatologie und InfektiologieOtto-von-Guericke-Universität Leipziger Str. 44 39120 Magdeburg Phone: 0391/6713100 Fax: 0391/6713105 Email: peter.malfertheiner@med.ovgu.de
